Clinical Complications, Mortality, and Healthcare Resource Utilization of Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Ontario, Canada: A Retrospective Cohort Study
L. Lilly(Vertex Pharmaceuticals (United States)), Kevin H.M. Kuo(University Health Network), Carlos Galera Peñaranda(Vertex Pharmaceuticals (United States)), Jillian Murray(Johns Hopkins University), Irène Wang(Cleveland Clinic), Calum S. Neish(Takeda (Canada)), Natalie Nightingale(IQVIA (United Kingdom)), Chuka Udeze(Vertex Pharmaceuticals (United States)), Nanxin Li(Genomics Institute of the Novartis Research Foundation)
Cited by 1
Related Papers
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
|Nature|2012|8.5k
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162